Sponsor Directory

AbbVie clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

816

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Atopic Dermatitis
Interventions: Lutikizumab, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 19
States / cities: Fountain Hills, Arizona • Los Angeles, California • Sacramento, California + 16 more

Conditions: Solid Tumors Harboring MET Amplification
Interventions: Telisotuzumab Adizutecan; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 18
States / cities: Beverly Hills, California • Duarte, California • Los Angeles, California + 14 more

Conditions: Healthy Volunteers
Interventions: Emraclidine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: Etentamig, Dexamethasone, Lenalidomide, Pomalidomide, Daratumumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 15
States / cities: Little Rock, Arkansas • Miami, Florida • Tampa, Florida + 11 more

Conditions: Bipolar I Disorder, Bipolar II Disorder
Interventions: Icalcaprant, Placebo for Icalcaprant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 33
States / cities: Huntsville, Alabama • Chandler, Arizona • Tucson, Arizona + 29 more

Conditions: Crohn's Disease
Interventions: Placebo for Risankizumab SC, Risankizumab IV, Placebo for Risankizumab IV, Risankizumab SC, Risankizumab On-Body Injector (OBI); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 1,336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 111
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 91 more

Conditions: Rheumatoid Arthritis
Interventions: Upadacitinib, Adalimumab, Upadacitinib Matching Placebo, Adalimumab Matching Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 487 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 85
States / cities: Flagstaff, Arizona • Glendale, Arizona • Peoria, Arizona + 75 more

Conditions: Healthy Volunteer
Interventions: ABBV-295, Placebo for ABBV-295; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Migraine
Interventions: Ubrogepant, Placebo for Ubrogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 103
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 92 more

Conditions: Hepatitis C
Interventions: Glecaprevir/pibrentasvir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Jacksonville, Florida + 5 more

Conditions: Crohn's Disease (CD)
Interventions: ABT-494; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 27
States / cities: La Jolla, California • San Francisco, California • Gainesville, Florida + 22 more

Conditions: Masseter Muscle Prominence
Interventions: BOTOX, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 20
States / cities: Los Angeles, California • Newport Beach, California • Vista, California + 14 more

About this AbbVie sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AbbVie is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AbbVie trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AbbVie clinical trials

Filter and sort this sponsor

Live official records

A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body of Adult Healthy Volunteers

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.

Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV

A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease

A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants

About this AbbVie sponsor directory page